RxDoctor Payments Data

Jonathan Donaldson, MD

Urology · Mt Pleasant, SCNPI 1881693026

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,550 of the $9,909 with a category attached, or 86.3%. It is spread thinly across 42 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.

$9,909in general payments, 2019–2025

Across 260 payments — averaging $38.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Boston Scientific$1K
  • Axonics, Inc.$1K
  • Coloplast$722
  • Johnson & Johnson$471
  • Dendreon Pharmaceuticals LLC$430
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$1,25913%
  • Food & beverage$8,55086%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,909 in reported general payments places this provider in the 80th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$522,865
Medicare patients
1,059
Services billed
10,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron149$129,209
MyrbetriqMirabegron61$60,269
OrgovyxRelugolix21$53,551
Tamsulosin Hcl214$3,516
Solifenacin Succinate34$2,868
Oxybutynin Chloride ErOxybutynin Chloride64$2,503
Finasteride120$2,072
Testosterone Cypionate42$1,692
Dutasteride38$1,433
Estradiol15$1,009
NitrofurantoinNitrofurantoin Macrocrystal50$978
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$860
Silodosin13$837
Doxycycline Hyclate84$809
Oxybutynin Chloride18$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$187$182,761170 claims
Astellas Pharma US IncMyrbetriq$202$60,26961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 196 urology providers in South Carolina.

Other urology in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →